.
MergerLinks Header Logo

Announced

Completed

Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals for $108m.

Financials

Edit Data
Transaction Value£79m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For98%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Completed

Private

Majority

biopharmaceutical company

Domestic

Single Bidder

United States

Pharmaceuticals

Acquisition

Friendly

Synopsis

Edit

Amneal, a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products, completed the acquisition of Kashiv Specialty Pharmaceuticals, a premier fully integrated specialty biopharmaceutical company, for $108m. "Our management and scientists are excited to be a part of Amneal Pharmaceuticals. Kashiv Specialty has helped Amneal develop many high value, complex generic products, and possesses tremendous know how and patented novel technologies for developing complex generic and specialty products. Going forward, Amneal will provide valuable strategic, operational, and infrastructure support for the rapid development and commercialization of our specialty portfolio, which consists of differentiated 505(b)2 products that will serve patient needs in neurology and endocrinology and provide significant organic growth for Amneal," Navnit Shah, Kashiv Specialty President and Chief Scientific Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US